[July 19, 2016]

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sagent Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) ("Sagent" or the "Company") relating to the proposed buyout of Sagent by Nichi-Iko Pharmaceutical Co., Ltd. The firm's investigation seeks to determine, among other things, whether the Company's Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company's shares of common stock.

Under the terms of the agreement, Sagent shareholders are anticipated to receive $21.75 in cash for each share of Sagent common stock held. The transaction may undervalue the Compny and would result in no real gain or a loss for many long-term shareholders of Sagent, especially given that the Company's 52-week high is $26.47. Additionally, according to Yahoo! Finance, at least one Wall Street analyst has issued a price target for Sagent stock at $25.00 per share.

If you currently own common stock of Sagent and believe that the proposed buyout price is too low, or you would like to learn more about the investigation being conducted by Brower Piven, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160719006441/en/

[ Back To TMCnet.com's Homepage ]